0000000000367796

AUTHOR

Uta Dirksen

showing 8 related works from this author

PanCareLIFE

2018

Aims: Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.Methods: PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohor…

MaleGerontologyCancer ResearchLongitudinal studyMedizinPilot ProjectsChildhood cancer survivors0302 clinical medicineNeoplasmsLYMPHOMAMedicineFertility preservationChild610 Medicine & healthEARLY MENOPAUSEOVARIAN-FUNCTIONmedia_commonSURVIVORSOUTCOMES030219 obstetrics & reproductive medicineFertility PreservationGENETIC-VARIATIONCHEMOTHERAPYEuropeOncologyChild Preschool030220 oncology & carcinogenesisCohortFemalemedicine.symptom360 Social problems & social servicesAdultQuality of lifeAdolescentHearing lossmedia_common.quotation_subjectFertilityGuidelinesYoung Adult03 medical and health sciencesQuality of life (healthcare)SDG 3 - Good Health and Well-beingHumansCHILDHOOD-CANCERbusiness.industryClinical study designLate effectsHEARING-LOSSInfant NewbornInfantOtotoxicityLong-Term CareGonadal impairmentLong-term careFeasibility StudiesbusinessFOLLOW-UPEuropean Journal of Cancer
researchProduct

Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene appr…

2021

Background: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. Methods: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743

OncologyInfertilityCancer ResearchCandidate genemedicine.medical_specialtyendocrine systemendocrine system diseasesMedizinAnti-Müllerian hormoneArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Childhood cancer survivors03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInterquartile rangeInternal medicineGenetic variationGenetic modelmedicineChemotherapyFertility preservationRC254-282030304 developmental biology0303 health sciencesbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensAnti-Müllerian hormonemedicine.diseaseOvarian functionCytochrome P450 genesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthOncology030220 oncology & carcinogenesisCohortbiology.proteinCandidate gene approachbusinessGeneral Economics Econometrics and FinanceCancers
researchProduct

Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival

2016

AbstractBackground: Malignant bone tumors are a rare group of childhood cancer.Materials and methods: This study describes incidence rates, survival probabilities, and time trends for 1831 children below 15 years of age with a bone tumor registered at the population-based German Childhood Cancer Registry between 1987 and 2011.Results: Overall age-standardized annual incidence rate (ASR) was 5.5 per million. Osteosarcomas (ASR 2.8) and Ewing tumors (ASR 2.6) were the most frequent diagnostic groups. The incidence of bone tumors overall tended to increase slightly over time by 0.7% each year on average. Thirty-nine of the bone tumor cases reported were subsequent primaries and not included in…

Male0301 basic medicinePediatricsmedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPopulationBone NeoplasmsSarcoma EwingAnnual incidence03 medical and health sciencesRare DiseasesSex Factors0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingRegistriesChildeducationSurvival analysisOsteosarcomaChemotherapyChildhood Cancer Registryeducation.field_of_studybusiness.industryTime trendsIncidenceIncidence (epidemiology)Age FactorsInfant NewbornInfantHematologyGeneral MedicineSurvival Analysis030104 developmental biologyOncologyChild Preschool030220 oncology & carcinogenesisFemalebusinessActa Oncologica
researchProduct

Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria

2013

In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from 80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs an…

medicine.medical_specialtyPediatricsbusiness.industryChildhood cancerHematologyPediatric cancerClinical trialOncologyInterimScale (social sciences)Pediatrics Perinatology and Child HealthTreatment intensitymedicineOverall survivalTumor boardIntensive care medicinebusinessPediatric Blood & Cancer
researchProduct

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatri…

2017

Heritable predisposition is an important cause of cancer in children and adolescents. Although a large number of cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more pediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. In a consensus meeting in the beginning of 2016, we convened experts in Human Genetics and Pediatric Hematology/Oncology to review the available data, to categorize the large amount of information, and to develop recommendations regarding when a cancer predisposition syndrome should be suspected in a young oncology patient. This review su…

0301 basic medicineHistoryMedizinGene Expression0302 clinical medicineNeoplasm Proteins/geneticsNeoplasmsChildGenetics (clinical)Societies Medicalddc:618HematologyJuvenile myelomonocytic leukemiaCancer predispositionSyndromeFocus Groups21st Century3. Good healthNeoplasm Proteins030220 oncology & carcinogenesisHematologic NeoplasmsGenetic Testing/methodsmedicine.medical_specialtyAdolescentGenetics MedicalGenetic CounselingHistory 21st CenturyMedical/history/instrumentation/methodsFamilial adenomatous polyposis03 medical and health sciencesInternal medicineGeneticsmedicineHumansFocus Groups/methodsGenetic Predisposition to DiseaseGenetic TestingIntensive care medicineGenetic Counseling/ethicsbusiness.industryHematologic Neoplasms/diagnosis/genetics/pathologyCancermedicine.diseasePediatric cancerHuman genetics030104 developmental biologyLi–Fraumeni syndromeNeoplasms/diagnosis/genetics/pathologyMutationMedical/historySocietiesbusinessAmerican journal of medical genetics. Part A
researchProduct

1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma

2012

12 páginas, 6 figuras, 1 tabla.-- et al.

AdultMaleCancer ResearchCandidate geneAdolescentDNA Copy Number VariationsUbiquitin-Protein Ligasesclinical outcomeBone NeoplasmsSarcoma EwingBiologyBioinformaticsPolymorphism Single NucleotideTranscriptomeIn vivoCell Line TumorGeneticsmedicineHumansChildMolecular BiologymicroarraysAgedCell ProliferationAged 80 and overCell CycleComputational BiologyInfantNuclear ProteinsMiddle Agedmedicine.disease1q GainIn vitroChromosomes Human Pair 1Child PreschoolCancer researchImmunohistochemistryFemaleCDT2SarcomaDNA microarrayEwing sarcomaComparative genomic hybridization
researchProduct

The first European interdisciplinary ewing sarcoma research summit.

2012

This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License.-- et al.

EpigenomicsCancer ResearchAlternative medicineMedizinComputingMilieux_LEGALASPECTSOFCOMPUTINGReview ArticleBioinformatics[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologydrug screen0302 clinical medicineDrug screenCancer genomicssignallingSarcomagenesis0303 health sciencessarcomagenesisSummitgeography.geographical_feature_categoryOpinion leadershipGenomicsLaboratory resultslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisanimal models3. Good healthAnimal modelsMetastatic Ewing SarcomaOncology030220 oncology & carcinogenesis[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]EpigeneticsSarcomaImmunotherapyPrioritizationmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/Cancerlcsh:RC254-28203 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicinegenomics030304 developmental biologyMedical educationgeographyepigeneticsbusiness.industrybiomarkers[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseClinical trialprognosisbusinessBiomarkersEwing sarcomaFrontiers in oncology
researchProduct

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer

2021

Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at a…

InfertilityAdultMalemedicine.medical_specialtyAdolescentfertility preservationmedia_common.quotation_subjectMEDLINEMedizinFertilityGuidelines as Topic03 medical and health sciences0302 clinical medicineCancer SurvivorsSDG 3 - Good Health and Well-beingNeoplasmsMedicineHumansgonadotoxic therapiesFertility preservationYoung adultGrading (education)Childmedia_commonchildhoodCancer030219 obstetrics & reproductive medicinebusiness.industryCancerGuidelinemedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicineDisease Progressionyoung adultFemalebusinessinfertilityreproductive medicineThe Lancet Oncology
researchProduct